AAPL 168.0 -0.8147% MSFT 411.84 -0.6609% GOOG 156.88 0.5641% GOOGL 155.47 0.693% AMZN 181.28 -1.1128% NVDA 840.35 -3.8666% META 494.17 -1.1185% TSLA 155.45 -1.0566% TSM 139.03 -0.5508% LLY 750.77 0.5397% V 272.69 0.4938% AVGO 1282.63 -3.4934% JPM 180.08 -0.3982% UNH 478.99 2.154% NVO 124.53 0.8748% WMT 59.65 -0.3175% LVMUY 170.745 -0.914% XOM 118.65 -0.0337% LVMHF 858.0 0.345% MA 460.16 0.0739%
Last update at 2024-04-17T20:13:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -29.13500M | -28.66700M | -16.77500M | -22.67400M | -34.95900M |
| Minority interest | - | - | - | - | - |
| Net income | -29.31200M | -28.72600M | -17.32600M | -22.65800M | -34.95900M |
| Selling general administrative | 14.01M | 17.55M | 8.03M | 7.77M | 7.28M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | 0.35M | - | -14.53000M | 3.00M |
| Reconciled depreciation | 0.07M | -0.05900M | -0.01300M | 0.02M | 0.03M |
| Ebit | -27.96400M | -28.28800M | -16.22300M | -22.31200M | -34.76800M |
| Ebitda | -27.89400M | -28.34700M | -16.23000M | -22.29600M | -34.74000M |
| Depreciation and amortization | 0.07M | -0.05900M | -0.00700M | 0.02M | 0.03M |
| Non operating income net other | - | - | -0.00700M | 0.00800M | 0.01M |
| Operating income | -27.89400M | -28.34700M | -16.22300M | -22.29600M | -34.74000M |
| Other operating expenses | 27.89M | 28.69M | 16.22M | 22.30M | 37.74M |
| Interest expense | 0.99M | 0.32M | 0.55M | 0.39M | 0.23M |
| Tax provision | - | - | - | - | - |
| Interest income | - | - | - | 0.39M | 0.23M |
| Net interest income | -0.99400M | -0.31800M | -0.54500M | -0.38600M | -0.23100M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.18M | 0.06M | 0.55M | -0.01600M | 0.01M |
| Total revenue | 0.00000M | 0.35M | 0.00000M | 0.00000M | 3.00M |
| Total operating expenses | 27.89M | 28.69M | 16.22M | 22.30M | 37.74M |
| Cost of revenue | - | - | - | 14.53M | 30.46M |
| Total other income expense net | -1.24100M | -0.32000M | -0.55200M | -0.37800M | -0.21900M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -29.13500M | -28.66700M | -16.77500M | -22.67400M | -34.95900M |
| Net income applicable to common shares | -29.13500M | -28.66700M | -16.77500M | -22.67400M | -34.95900M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 19.47M | 26.56M | 37.44M | 18.12M | 40.65M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.80M | 0.86M | 0.78M | 0.85M | 1.50M |
| Total liab | 26.62M | 14.84M | 12.37M | 15.42M | 19.21M |
| Total stockholder equity | -7.15100M | 11.71M | 25.07M | 2.70M | 21.44M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 8.64M | 7.34M | 5.68M | 9.23M | 12.41M |
| Common stock | 0.02M | 0.02M | 0.01M | 0.00400M | 0.03M |
| Capital stock | 0.02M | 0.02M | 0.01M | 0.00400M | 0.03M |
| Retained earnings | -236.91100M | -207.77600M | -179.10900M | -162.33400M | -139.66000M |
| Other liab | 3.28M | 1.17M | 0.43M | 0.28M | 0.37M |
| Good will | - | - | - | - | - |
| Other assets | 0.07M | 1.62M | 0.51M | 0.84M | - |
| Cash | 17.43M | 24.07M | 32.13M | 16.41M | 25.14M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 22.37M | 13.68M | 10.54M | 11.83M | 13.49M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -7.62600M | -22.68100M | -27.60400M | -11.06900M | -18.70900M |
| Short term debt | 9.81M | 1.39M | 3.14M | 2.60M | 1.08M |
| Short long term debt | 9.81M | 1.39M | 2.72M | 2.60M | 1.08M |
| Short long term debt total | 9.81M | 1.39M | 4.53M | 5.34M | 6.43M |
| Other stockholder equity | 229.74M | 219.47M | 204.17M | 165.03M | 161.20M |
| Property plant equipment | 1.17M | 0.05M | 0.02M | 0.02M | 0.04M |
| Total current assets | 18.23M | 24.94M | 36.91M | 17.26M | 40.60M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | -7.15100M | 11.71M | 25.07M | 2.70M | 21.44M |
| Short term investments | - | 0.00000M | 4.00M | 0.00000M | 13.97M |
| Net receivables | - | - | - | - | - |
| Long term debt | - | - | 1.39M | 2.74M | 5.34M |
| Inventory | - | - | - | - | - |
| Accounts payable | 3.92M | 4.94M | 1.73M | 1.35M | 1.46M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | -0.15000M | -0.12800M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.01M | 0.00400M | 0.03M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -179.10900M | -162.33400M | -139.66000M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1.19M | 1.57M | 0.51M | 0.84M | 0.04M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1.24M | 1.62M | 0.52M | 0.86M | 0.04M |
| Capital lease obligations | 0.20M | 0.15M | 0.42M | - | - |
| Long term debt total | - | - | 1.39M | 2.74M | 5.34M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.01700M | 4.00M | -3.99800M | 14.02M | -8.86900M |
| Change to liabilities | -0.23300M | 4.68M | 0.23M | -0.10900M | -0.03000M |
| Total cashflows from investing activities | -0.01700M | 3.95M | -4.00300M | 14.02M | -8.86900M |
| Net borrowings | 8.28M | -2.80000M | -1.40000M | -1.40000M | -1.32000M |
| Total cash from financing activities | 19.68M | 10.56M | 36.76M | 0.91M | 35.32M |
| Change to operating activities | -0.00600M | -0.13800M | 0.30M | 0.54M | 0.06M |
| Net income | -29.13500M | -28.66700M | -16.77500M | -22.67400M | -34.95900M |
| Change in cash | -6.57200M | -8.05900M | 15.72M | -8.72400M | -4.33100M |
| Begin period cash flow | 24.07M | 32.13M | 16.41M | 25.14M | 29.47M |
| End period cash flow | 17.50M | 24.07M | 32.13M | 16.41M | 25.14M |
| Total cash from operating activities | -26.23900M | -22.57100M | -17.04200M | -23.65000M | -30.78300M |
| Issuance of capital stock | 7.88M | 13.21M | 38.16M | 2.29M | 36.46M |
| Depreciation | 0.07M | -0.05900M | -0.01300M | 0.02M | 0.03M |
| Other cashflows from investing activities | - | - | - | 14.02M | -8.86900M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | - | - | - | - |
| Sale purchase of stock | - | - | - | 0.03M | 0.26M |
| Other cashflows from financing activities | 13.48M | 0.15M | 0.00200M | 0.01M | 7.18M |
| Change to netincome | 2.68M | 1.52M | 1.28M | 1.86M | 2.94M |
| Capital expenditures | 0.02M | 0.05M | 0.00500M | 0.00500M | 0.00500M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | -1.83900M | -2.77600M | 1.25M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | 15.72M | -8.72400M | -4.33100M |
| Change in working capital | -0.23900M | 4.54M | -1.57900M | -2.87900M | 4.20M |
| Stock based compensation | 2.04M | 1.77M | 1.03M | 1.62M | 2.67M |
| Other non cash items | 1.02M | -0.16400M | 0.29M | 0.32M | -2.62300M |
| Free cash flow | -26.25600M | -22.61900M | -17.04700M | -23.65000M | -30.78300M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TCON TRACON Pharmaceuticals Inc |
0.58 33.92% | 2.29 | - | - | 0.60 | 11.83 | 77.05 | 0.58 |
| NVO Novo Nordisk A/S |
1.08 0.87% | 124.53 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.41 1.15% | 124.15 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-1.07 0.27% | 393.10 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
0.13 0.15% | 87.96 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
4350 La Jolla Village Drive, San Diego, CA, United States, 92122
| Name | Title | Year Born |
|---|---|---|
| Dr. Charles P. Theuer M.D., Ph.D. | CEO, Pres & Director | 1964 |
| Mr. Scott B. Brown CPA, M.S. | Chief Financial Officer | 1981 |
| Ms. Bonne Adams | Exec. VP of Clinical Operations | 1977 |
| Mr. Shahe Garabedian | Sr. VP & Head of Quality Assurance | NA |
| Dr. James L. Freddo | Chief Medical Officer | 1955 |
| Mr. Ya Huang | Exec. Director of Statistical Programming | NA |
| Dr. Brenda Marczi Pharm.D., Pharmd Mba | Sr. VP of Regulatory Affairs | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...